Table 1.
Background characteristics of patients in the placebo and tenapanor groups
| Parameter | Placebo (N = 24) | Tenapanor 30 mg dose titration (N = 23) |
|---|---|---|
| Sex | ||
| Female | 9 (37.5) | 4 (17.4) |
| Male | 15 (62.5) | 19 (82.6) |
| Age (mean [SD]), years | 59.4 (9.2) | 62.1 (8.5) |
| Height, cm | 164.09 (8.38) | 165.81 (8.52) |
| Weight on the day before dialysis (mean [SD]), kg | 68.27 (16.97) | 65.27 (9.25) |
| Weight on the day after dialysis (mean [SD]), kg | 64.91 (16.50) | 62.35 (8.97) |
| BMI (mean [SD]), kg/m2 | 25.14 (4.79) | 23.71 (2.75) |
| Primary disease | ||
| Diabetic nephropathy | 9 (37.5) | 10 (43.5) |
| Chronic glomerulonephritis | 9 (37.5) | 10 (43.5) |
| Nephrosclerosis | 1 (4.2) | 0 |
| Polycystic kidney | 1 (4.2) | 0 |
| Chronic pyelonephritis | 0 | 0 |
| Others | 4 (16.7) | 3 (13.0) |
| Phosphate binder at day 1 | ||
| Calcium carbonate | 16 (66.7) | 19 (82.6) |
| Sevelamer hydrochloride | 5 (20.8) | 4 (17.4) |
| Lanthanum carbonate | 9 (37.5) | 5 (21.7) |
| Bixalomer | 2 (8.3) | 3 (13.0) |
| Sucroferric oxyhydroxide | 2 (8.3) | 3 (13.0) |
| Ferric citrate hydrate | 8 (33.3) | 6 (26.1) |
| Serum phosphorus level (mean [SD]), mg/dL | ||
| At enrollment | 7.38 (0.83) | 7.18 (0.73) |
| At baseline | 7.01 (1.25) | 6.77 (0.88) |
| iPTH (mean [SD]), pg/mL | ||
| At enrollment | 202.5 (161.1) | 172.7 (116.9) |
| At baseline | 174.7 (130.4) | 168.0 (129.9) |
Data in the table are n (%), unless otherwise indicated. iPTH, intact parathyroid hormone; SD, standard deviation.